Tepha Inc. has raised $11.3 million in equity funding from 38 unnamed investors, according to SEC filings.

Tepha, Inc. is a medical device firm pursuing the development and commercialization of innovative products based on the Company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates (a.k.a. PHAs), which may be tailored to meet unmet needs for medical devices in multiple fields. Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention.

TephaFLEX polymer is the first of the company's PHA materials to be used in FDA cleared medical devices. Products made from TephaFLEX polymer include surgical suture, surgical mesh, surgical film, and a composite mesh. Devices that are currently in development could lead to more complex products, including devices for anterior cruciate ligament repair, intracardiac defect closure, and absorbable cardiovascular stents.